Phase 2 Glaucoma Trial, Recruiting NCT05694858 Sponsor: Universiti Kebangsaan Malaysia Medical Centre Condition: Glaucoma
Back to Glaucoma

Phase 2 Glaucoma Trial, Recruiting

NCT05694858
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who need a blood draw (needle into a vein) as part of preparation for an eye procedure

Who may not be able to join:

  • People who have previously had a sensitivity reaction or allergic reaction to lignocaine (a type of local anaesthetic)
  • People who have previously had an allergic reaction to any of the materials used in this study, including plaster, electrodes, maltose, Polyvinyl Alcohol (PVA), or Polyethylene Terephthalate (PET)
  • People who have taken any pain-relieving medication within 24 hours before the procedure
  • People who have a widespread skin condition or rash
  • People who are agitated, restless, or unable to cooperate during the procedure
  • People who are unable to communicate, or who are deaf or mute
  • People who are taking sleeping medications or long-term pain relief medications
  • People who have a psychiatric condition
  • People who have a liver condition affecting how the liver works
  • People who are taking certain medications that affect how the liver processes drugs — including some antibiotics, heart medications, and others (confirm with trial site) — as these may interact with lignocaine
  • People for whom the first attempt at placing the needle into a vein was unsuccessful after the study patch was applied

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: FOOK CHOE CHEAH, MD, PhD, MRCPCH, FACULTY OF MEDICINE, UNIVERSITI KEBANGSAAN MALAYSIA (UKM)

Phone: +60172107299

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Universiti Kebangsaan Malaysia Medical Centre
Registry
ClinicalTrials.gov
Start date
17 February 2025
Est. completion
11 December 2026

Where this trial is recruiting

🇲🇾 Malaysia

Primary endpoints

Visual Analogue Score (VAS); Skin Conductance Algesimeter Index

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov